Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Glaukos ( (GKOS) ) has provided an update.
In May 2026, Glaukos released an investor presentation outlining its strategy to drive long-term growth by leading a shift toward interventional glaucoma and interventional keratoconus care. The company highlighted its strong topline revenue growth, industry-leading pipeline and role in creating new markets through dropless, procedural and sustained-release therapies designed to reduce patient dependence on topical eye drops.
The materials emphasized Glaukos’s positioning around its iDose TR long-duration travoprost implant, the first FDA-approved glaucoma procedural pharmaceutical for re-administration as of January 2026, which aims to address widespread non-compliance with topical drops. Glaukos also pointed to follow-on iDose platform candidates and its iStent infinite micro-invasive glaucoma surgery technology as pillars of a proactive, procedure-based glaucoma treatment paradigm, underscoring favorable clinical data, surgeon adoption trends and the potential to anchor care across the disease spectrum.
The most recent analyst rating on (GKOS) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
The score is driven by strong technical momentum and a notably positive earnings update (record results and raised guidance with expanding gross margins). This is tempered by weak underlying financial performance due to ongoing losses and cash burn, and limited valuation support given the negative P/E and no dividend.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
Glaukos Corporation is a hybrid pharmaceutical-device company focused on innovative treatments for chronic eye diseases, targeting large and underserved patient populations. Its portfolio spans micro-scale implants, sustained-release drug delivery and bio-activated therapies, with 12 commercialized products, 13 disclosed pipeline programs and substantial R&D investment since 2018 to expand its presence in glaucoma, keratoconus, myopia, blepharitis and retinal diseases.
Average Trading Volume: 758,552
Technical Sentiment Signal: Buy
Current Market Cap: $8.21B
See more data about GKOS stock on TipRanks’ Stock Analysis page.